Site Contents


Program Features

Satellite Meeting hosted by Berlex Laboratories Inc. Tuesday, June 5, 0900 – 1100

The Emerging Role of 5-Ala PDT in Dermatology

Chairs: C.A. Morton, A. Oseroff

5-aminolevulinic acid has been investigated in dermatological indications for many years. Now, the first commercially available topical photosensitizer 5-Ala solution (Levulan“) has been registered for the treatment of actinic keratoses. This symposium will present an overview of the clinical data of Levulan and will give an outlook on the broad range of potential applications of 5-Ala PDT in dermatology.

Stan B. Brown – The advantages of 5-Ala and 5-Ala its derivatives in dermatology

R.M. Szeimies – Institutional overview of PDT (and PD) in Dermatology – The Regensburg Experience

E.W.B. Jeffes III – Levulan, the first topical photosensitizer for the treatment of Aks

C.A. Morton – Is PDT superior to standard treatments?

A. Oseroff – Future applications of PDT in Dermatology – The Roswell Park Experience

Satellite Meeting hosted by Axcan Scandipharm Inc. Tuesday, June 5, 1300 – 1500

Photodynamic Therapy. Gastrointestinal applications

Chair: François Martin, MD

This symposium will present efficacy and safety data of photodynamic therapy with Photofrin in gastrointestinal indications. In addition some candidate application will be presented.

B.F. Overholt, MD – Long-term follow-up on Photofrin/PDT treatment of Barrett’s esophagus

Charles Lightdale, MD – Photofrin/PDT in the treatment of Obstructive Esophageal Cancer

Maria Anne E.J. Ortner, MD – Photofrin/PDT in the treatment of Cholangiocarcinoma

Greg Haber, MD– Future applications of Photofrin/PDT in other GI conditions

Satellite Meeting hosted by QLT Inc. Tuesday, June 5, 1600 – 1800

Expanding Horizons in PDT
Chair: Mohammad Azab

Over the past several years, extensive research has been conducted to evaluate photodynamic therapy for treatment of conditions in oncology, ophthalmology, autoimmunity and cardiology. This symposium is designed to acquaint PDT researchers and practitioners from a broad spectrum of fields with the wide-ranging research and development efforts that have been undertaken using verteporfin and other photosensitizers.

Dr. Mohammad Azab, MD and Senior Vice-President, Clinical Research and Medical Affairs for QLT will chair this symposium, during which a panel of distinguished physicians and scientists will present information on preclinical and clinical studies that have recently been conducted within these four areas.

The presentation agenda is as follows:.

16:00 – 16:30
Michael J. Potter, MD – Visudyne™ Therapy for the Treatment of Classic and Occult Choroidal Neovascularization in Age-related Macular Degeneration

The wet form of age-related macular degeneration (AMD) is the leading cause of legal blindness in people over the age of 50 in the Western world. Results from the TAP and VIP studies have demonstrated a significant treatment effect for verteporfin therapy in patients with predominantly classic and occult CNV lesions. Two year follow-up from both trials will be presented.

16:30 – 16:50
David Saperstein, MD – Clinical Trials Using Visudyne™ Therapy for Choroidal Neovascularization Secondary to Pathologic Myopia (VIP - PM Trial) and Ocular Histoplasmosis Syndrome (VOH Trial)

In this session, the effects on visual acuity of patients with subfoveal choroidal neovascular membranes (CNV) in pathologic myopia (PM) and ocular histoplasmosis syndrome (OHS) who were treated with verteporfin will be presented.

16:50 – 17:05
Sandra Gollnick, PhD – Photodynamic Vaccination: Review and Data Presentation

One of the potential advantages of photodynamic therapy over other types of cancer treatment is its ability to enhance the host anti-tumor immune response. Studies that have sought to exploit the ability of PDT to enhance tumor immunogenicity by using PDT-generated tumor cell lysates as tumor vaccines have shown that PDT vaccines are effective at suppressing subsequent tumor growth via the generation of tumor specific T-cells.

17:05 – 17:20
Nancy Oleinick, PhD – PDT in Signal Modulation and Apoptosis: Review and Data Presentation

Photodynamic therapy produces localized oxidative damage in cells at or near the intracellular site of photosensitizer binding, resulting in oxidative stress that is highly efficient at activating cellular signaling pathways and prompt apoptosis. This presentation will review the evidence for the intersection of constitutive and PDT-regulated pathways in PDT-induced apoptosis.

17:20 – 17:30
Philippe Margaron, PhD – Review of PDT in Cardiovascular Medicine

Researchers have explored photodynamic therapy as a modali-ty for the reduction and stabilization of atherosclerotic plaques and the inhibition of intimal hyperplasia, and a number of clinical trials are underway. This presentation will first summarize the scientific rationales for PDT in cardiovascular applications before reviewing the approaches being investigated today by the groups actively working in this field.

17:30 – 17:40
Harvey Lui, MD – Review of Verteporfin PDT in Skin Cancer

Historically PDT was first used for treating patients with skin tumors, and this has been the case with verteporfin as well. Early studies of patients with non-melanoma skin cancer confirmed the short duration of systemic photosensitivity with verteporfin, while demonstrating the potential for effective control of primary and metastatic skin tumors. More recent studies have been designed to explore the role of verteporfin-based PDT in patients with multiple skin tumors in terms of both tumor eradication and cosmetic outcome.

17:40 – 18:00
Q & A

Plenary Sessions

Each morning will feature two plenary sessions, each highlighting a clinical or basic aspect of photodynamic medicine. These talks will be given by leaders in the field, many of whom pioneered groundbreaking research. We will also look to the future expectations in this exciting field.

Concurrent Sessions

The afternoon sessions will provide in-depth information for specialists as we focus on specific areas of photodynamic medicine and its uses, challenges and successes.

Interest Group Breakfast
Thursday, June 7th, 7:00AM

Join colleagues for this informal gathering over breakfast and share your experiences. Tickets are available at the Congress Registration Desk.
IPA 8th World Congress of Photodynamic Medicine  
Download the PDF version
of this document.

Updated: May 27, 2001